 - Subject is receiving therapy with one of the following drugs either concurrently or within 28 days prior to Baseline Visit 2: alpha-methyl dopa, metoclopramide, reserpine, neuroleptics except specific atypical neuroleptics: olanzapine, ziprasidone, aripiprazole, clozapine, quetiapine, monoamine oxidase A MAO-A inhibitors, methylphenidate, or amphetamine 